Physician profile
Michael E Dangelo
NPI 1720015639
$2,500.40
in general payments reported to CMS, 2019-2025
22 companies · $542 in 2025
The $542 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.96 · 2020: $173 · 2021: $298 · 2022: $304 · 2023: $656 · 2024: $490 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $362.37 | 2020-2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $333.74 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $327.29 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $294.10 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.61 | 2023-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $179.68 | 2023-2025 | Optimizer, Optimizer |
| Abbott Laboratories | $176.89 | 2021-2025 | Amplatzer Amulet, Jot Dx |
| Lantheus Medical Imaging, INC. | $106.42 | 2019-2022 | |
| Bridgebio Pharma, INC. | $54.65 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals Lp | $51.81 | 2022-2025 | Farxiga |
| Astellas Pharma US INC | $51.75 | 2023 | Myrbetriq |
| Medtronic, INC. | $50.23 | 2021-2025 | Symplicity G3 |
| Sanofi-Aventis U.S. LLC | $43.39 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.15 | 2021-2024 | Lifevest |
| Amgen INC. | $34.94 | 2023 | Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28.37 | 2021-2024 | Xarelto |
| Atricure, INC. | $28.05 | 2021 | |
| Alnylam Pharmaceuticals INC. | $23.86 | 2023 | Onpattro |
| Scpharmaceuticals INC. | $16.32 | 2024 | |
| Daiichi Sankyo INC. | $15.06 | 2023 | Injectafer |
| Boston Scientific Corporation | $14.68 | 2020 | |
| Esperion Therapeutics, INC. | $13.04 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dangelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.